Interaction between cerebrovascular disease and Alzheimer pathology

Current Opinion in Psychiatry

Volumn 29, Issue 2, 2016, Pages 168-173

  Saito, Satoshi ^a   Ihara, Masafumi ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Alzheimer's disease; cerebral amyloid angiopathy; cerebrovascular disease; clearance; small vessel disease

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; ADVANCED GLYCATION END PRODUCT;

ALZHEIMER DISEASE; BASIC RESEARCH; BRAIN BLOOD FLOW; BRAIN PERFUSION; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; HUMAN; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN HOMEOSTASIS; PROTEIN METABOLISM; REVIEW; SMOOTH MUSCLE FIBER; TRANSLATIONAL RESEARCH; VASCULAR DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BRAIN CIRCULATION; CLINICAL TRIAL (TOPIC); DEMENTIA; DISEASE MODEL; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS AS TOPIC; DEMENTIA; DISEASE MODELS, ANIMAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICE, TRANSGENIC; RISK FACTORS;

EID: 84958114093     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000239     Document Type: Review

References (65)

1. Ryan NS, Rossor MN, Fox NC. Alzheimer's disease in the 100 years since Alzheimer's death. Brain 2015; 138:3816-3821.
2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:263-269.
3. Provenzano FA, Muraskin J, Tosto G, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol 2013; 70:455-461.
4. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med 2014; 12:206.
5. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136:2697-2706.
6. Hama H, Hioki H, Namiki K, et al. Scale S: an optical clearing palette for biological imaging. Nat Neurosci 2015; 18:1518-1529.
7. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement 2015; 11:710-717.
8. Sato N, Morishita R. The roles of lipid and glucose metabolism in modulation of b-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Front Aging Neurosci 2015; 7:199.
9. Akinyemi RO, Mukaetova-Ladinska EB, Attems J, et al. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr Alzheimer Res 2013; 10:642-653.
10. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015; 385:2255-2263.
11. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med 2013; 369:2275-2277.
12. Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013; 80:1888-1894.
13. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 2013; 382:1405-1412.
14. Gupta A, Iadecola C. Impaired Ab clearance: a potential link between atherosclerosis and Alzheimer's disease. Front Aging Neurosci 2015; 7:115.
15. Di Marco LY, Venneri A, Farkas E, et al. Vascular dysfunction in the pathogenesis of Alzheimer's disease: a review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis 2015; 82:593-606.
16. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:689-701.
17. Esiri M, Chance S, Joachim C, et al. Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. Brain Pathol 2015; 25:51-62.
18. Weller RO, Hawkes CA, Carare RO, et al. Does the difference between PART and Alzheimer's disease lie in the age-related changes in cerebral arteries that trigger the accumulation of Ab and propagation of tau? Acta Neuropathol 2015; 129:763-766.
19. Yamada M. Cerebral amyloid angiopathy: emerging concepts. J Stroke 2015; 17:17-30.
20. Wiseman FK, Al-Janabi T, Hardy J, et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat Rev Neurosci 2015; 16:564-574.
21. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS b-amyloid in Alzheimer's disease. Science 2010; 330:1774.
22. Davis J, Xu F, Miao J, et al. Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double Ab in human AbPP transgenic mice. Neurobiol Aging 2006; 27:946-954.
23. Saito S, Ihara M. New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci 2014; 6:290.
24. Ramanathan A, Nelson AR, Sagare AP, et al. Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer's disease: the role, regulation and restoration of LRP1. Front Aging Neurosci 2015; 7:136.
25. Montagne A, Barnes SR, Sweeney MD, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85:296-302.
26. Halliday MR, Rege SV, Ma Q, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab 2016; 36:216-227.
27. Arbel-Ornath M, Hudry E, Eikermann-Haerter K, et al. Interstitial fluid drainage is impaired in ischemic stroke and Alzheimer's disease mouse models. Acta Neuropathol 2013; 126:353-364.
28. Morris AW, Carare RO, Schreiber S, et al. The cerebrovascular basement membrane: role in the clearance of b-amyloid and cerebral amyloid angiopathy. Front Aging Neurosci 2014; 6:251.
29. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523:337-341.
30. Weller RO, Hawkes CA, Kalaria RN, et al. White matter changes in dementia: role of impaired drainage of interstitial fluid. Brain Pathol 2015; 25:63-78.
31. Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 2015; 11:457-470.
32. Morrone CD, Liu M, Black SE, et al. Interaction between therapeutic interventions for Alzheimer's disease and physiological Ab clearance mechanisms. Front Aging Neurosci 2015; 7:64.
33. Lai AY, Dorr A, Thomason LA, et al. Venular degeneration leads to vascular dysfunction in a transgenic model of Alzheimer's disease. Brain 2015; 138:1046-1058.
34. Sharp MK, Diem AK, Weller RO, et al. Peristalsis with oscillating flow resistance: a mechanism for periarterial clearance of amyloid beta from the brain. Ann Biomed Eng 2016. [Epub ahead of print]
35. Iliff JJ, Wang M, Zeppenfeld DM, et al. Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain. J Neurosci 2013; 33:18190-18199.
36. Hughes TM, Kuller LH, Barinas-Mitchell EJ, et al. Arterial stiffness and bamyloid progression in nondemented elderly adults. JAMA Neurol 2014; 71:562-568.
37. Nation DA, Edmonds EC, Bangen KJ, et al. Pulse pressure in relation to taumediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. JAMA Neurol 2015; 72:546-553.
38. Reijmer YD, Fotiadis P, Martinez-Ramirez S, et al. Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. Brain 2015; 138:179-188.
39. Greenberg SM, Al-Shahi Salman R, Biessels GJ, et al. Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol 2014; 13:419-428.
40. Charidimou A, Linn J, Vernooij MW, et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 2015; 138:2126-2139.
41. Shoamanesh A, Martinez-Ramirez S, Oliveira-Filho J, et al. Interrelationship of superficial siderosis and microbleeds in cerebral amyloid angiopathy. Neurology 2014; 83:1838-1843.
42. Kövari E, Charidimou A, Herrmann FR, et al. No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy. Acta Neuropathol Commun 2015; 3:49.
43. Chiang GC, Cruz Hernandez JC, Kantarci K, et al. Cerebral Microbleeds, CSF p-Tau, and cognitive decline: significance of anatomic distribution. AJNR Am J Neuroradiol 2015; 36:1635-1641.
44. Saito S, Yamamoto Y, Ihara M. Mild cognitive impairment: at the crossroad of neurodegeneration and vascular dysfunction. Curr Alzheimer Res 2015; 12:507-512.
45. Okamoto Y, Yamamoto T, Kalaria RN, et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123:381-394.
46. Ii Y, Maeda M, Kida H, et al. In vivo detection of cortical microinfarcts on ultrahigh-field MRI. J Neuroimaging 2013; 23:28-32.
47. van Rooden S, Goos JD, vanOpstal AM, et al. Increasednumber of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology 2014; 270:205-211.
48. Westover MB, Bianchi MT, Yang C, et al. Estimating cerebral microinfarct burden from autopsy samples. Neurology 2013; 80:1365-1369.
49. van Veluw SJ, Zwanenburg JJ, Rozemuller AJ, et al. The spectrum of MR detectable cortical microinfarcts: a classification study with 7-tesla postmortem MRI and histopathology. J Cereb Blood Flow Metab 2015; 35:676-683.
50. van Dalen JW, Scuric EE, van Veluw SJ, et al. Cortical microinfarcts detected in vivo on 3 Tesla MRI: clinical and radiological correlates. Stroke 2015; 46:255-257.
51. Love S, Miners JS. White matter hypoperfusion and damage in dementia: postmortem assessment. Brain Pathol 2015; 25:99-107.
52. Reijmer YD, van Veluw SJ, Greenberg SM. Ischemic brain injury in cerebral amyloid angiopathy. J Cereb Blood Flow Metab 2016; 36:40-54.
53. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. Neurology 2014; 83:794-800.
54. Langley GR. Considering a new paradigm for Alzheimer's disease research. Drug Discov Today 2014; 19:1114-1124.
55. Iliff JJ, Chen MJ, Plog BA, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci 2014; 34:16180-16193.
56. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013; 79:1094-1108.
57. Shineman DW, Alam J, Anderson M, et al. Overcoming obstacles to repurposing for neurodegenerative disease. Ann Clin Transl Neurol 2014; 1:512-518.
58. Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid b-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122:1377-1392.
59. The US National Institutes of Health. Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease (STEADFAST), 2014. https://clinicaltrials.gov/ct2/show/NCT02080364. [Accessed 28 November 2015].
60. Burstein AH, Grimes I, Galasko DR, et al. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol 2014; 14:12.
61. Maki T, Okamoto Y, Carare RO, et al. Phosphodiesterase III inhibitor promotes drainage of cerebrovascular b-amyloid. Ann Clin Transl Neurol 2014; 1:519-533.
62. Taguchi A, Takata Y, Ihara M, et al. Cilostazol improves cognitive function in patients with mild cognitive impairment: a retrospective analysis. Psychogeriatrics 2013; 13:164-169.
63. Ihara M, Nishino M, Taguchi A, et al. Cilostazol add-on therapy in patients with mild dementia receiving donepezil: a retrospective study. PLoS One 2014; 9:e89516.
64. Sakurai H, Hanyu H, Sato T, et al. Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: a pilot study. Geriatr Gerontol Int 2013; 13:90-97.
65. The US National Institutes of Health. A trial of cilostazol in patients with mild cognitive impairment (COMCID), 2015. https://clinicaltrials.gov/ct2/show/ NCT02491268. [Accessed 28 November 2015]